HP518 - Dose Escalation

DRUG2 trials

Sponsors

Hinova Pharmaceuticals Aus Pty Ltd, Hinova Pharmaceuticals Inc.

Conditions

Metastatic Castration-resistant Prostate Cancer

Phase 1

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

CompletedNCT05252364

Hinova Pharmaceuticals Aus Pty LtdMetastatic Castration-resistant Prostate Cancer

Start: 2021-12-14End: 2024-01-22Updated: 2024-03-21

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

RecruitingNCT06155084

Hinova Pharmaceuticals Inc.Metastatic Castration-resistant Prostate Cancer

Start: 2023-12-26End: 2026-09-30Target: 84Updated: 2025-12-22

Related Papers

Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity.

2025-04-283 citations

Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2024-06-012 citations

Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2024-01-295 citations